18407810. REMOTE CARDIOTOXICITY MONITORING simplified abstract (ZOLL Medical Corporation)
Contents
REMOTE CARDIOTOXICITY MONITORING
Organization Name
Inventor(s)
Bahar Davoudi of Pittsburgh PA (US)
Kent J Volosin of Mars PA (US)
REMOTE CARDIOTOXICITY MONITORING - A simplified explanation of the abstract
This abstract first appeared for US patent application 18407810 titled 'REMOTE CARDIOTOXICITY MONITORING
The wearable cardiotoxicity monitoring system described in the patent application is designed to continuously monitor cardiotoxicity biosignal markers in oncology patients using a wearable device with biosignal sensors.
- The system includes externally applied biosignal sensors such as ECG electrodes and non-ECG physiological sensors to capture biosignals from the patient.
- A controller transmits the biosignal data to a remote server for analysis.
- The remote server's processor analyzes the data to identify cardiotoxicity biosignal markers associated with heart failure from chemotherapy and radiation therapy.
- Based on the identified markers, the system determines the current status of cardiotoxicity in the patient and generates an output.
Potential Applications: - Monitoring cardiotoxicity in oncology patients undergoing chemotherapy and radiation therapy. - Providing early detection of heart failure caused by cardiotoxicity. - Enabling remote monitoring of patients' cardiac health.
Problems Solved: - Lack of continuous monitoring for cardiotoxicity in oncology patients. - Delayed detection of heart failure symptoms in patients undergoing cancer treatment. - Limited access to real-time cardiac health data for healthcare providers.
Benefits: - Early detection of cardiotoxicity can lead to timely intervention and improved patient outcomes. - Remote monitoring allows for convenient and non-invasive monitoring of cardiac health. - Continuous monitoring provides a comprehensive view of the patient's cardiac status over time.
Commercial Applications: Title: "Wearable Cardiotoxicity Monitoring System for Oncology Patients" This technology can be utilized in healthcare settings, oncology clinics, and research institutions to enhance patient care, improve treatment outcomes, and advance research in cardiotoxicity associated with cancer therapies.
Questions about the technology: 1. How does the wearable device ensure accurate and reliable monitoring of cardiotoxicity biosignal markers? 2. What are the potential implications of early detection of cardiotoxicity in oncology patients for their treatment and prognosis?
Original Abstract Submitted
A wearable cardiotoxicity monitoring system for monitoring cardiotoxicity biosignal markers in oncology patients is provided. The system includes a wearable cardiotoxicity monitoring device configured for long-term, continuous wear by a patient, including externally applied biosignal sensors configured to sense biosignal(s) from the patient and a controller. The externally applied biosignal sensors include ECG electrodes and at least one non-ECG physiological sensor. The controller is configured to transmit biosignal-based data based on the sensed biosignal(s) to a remote server. The system further includes the remote server, including a memory and a processor. The processor is configured to receive the biosignal-based data, analyze the biosignal-based data to identify cardiotoxicity biosignal marker(s) associated with heart failure caused by chemotherapy and/or radiation therapy cardiotoxicity, determine a current status of cardiotoxicity in the patient based on the cardiotoxicity biosignal marker(s), and generate an output based on the current status of cardiotoxicity.
